Parkinson's Disease
With the advent of major organizations like the Michael J. Fox Foundation, Parkinson's research has never been busier. Current trials have focused on new symptomatic therapies and new methods of early diagnosis.
| Condition(s) | Type of Drug | Phase | Add-On | Comparator | Duration | Open Label Extension |
|---|---|---|---|---|---|---|
| New Onset Parkinson's Disease | Novel Oral Dopamine Agonist | III | No | Placebo | 24 weeks | 9 months |
| Mild to Moderate Parkinson's Disease | Novel Oral Dopamine Agonist | III | Yes | Placebo | 24 weeks | 9 months |
| Moderate to Advanced Parkinson's Disease | Carbidopa/Levodopa Continuous Subdermal infusion | III | Yes | Sham infusion | 12 months | Yes |
| Dyskinesias in Parkinson's Disease | Novel oral agent | II | Yes | 50% | 12 weeks | No |
| Dyskinesias in Parkinson's Disease | Novel oral agent | II | Yes | 33% | 1 year | No |
Response Form
If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!
- Stephen S. Flitman, MD, Medical Director
